NCT00614393 2018-08-08Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)Merck Sharp & Dohme LLCPhase 2 Completed558 enrolled 17 charts
NCT00851045 2015-10-12Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal CancerBristol-Myers SquibbPhase 2 Completed17 enrolled